Creation of a long-acting nanoformulated dolutegravir

Potent antiretroviral activities and a barrier to viral resistance characterize the human immunodeficiency virus type one (HIV-1) integrase strand transfer inhibitor dolutegravir (DTG). Herein, a long-acting parenteral DTG was created through chemical modification to improve treatment outcomes. A hy...

Descripción completa

Detalles Bibliográficos
Autores principales: Sillman, Brady, Bade, Aditya N., Dash, Prasanta K., Bhargavan, Biju, Kocher, Ted, Mathews, Saumi, Su, Hang, Kanmogne, Georgette D., Poluektova, Larisa Y., Gorantla, Santhi, McMillan, JoEllyn, Gautam, Nagsen, Alnouti, Yazen, Edagwa, Benson, Gendelman, Howard E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5799307/
https://www.ncbi.nlm.nih.gov/pubmed/29402886
http://dx.doi.org/10.1038/s41467-018-02885-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5799307/
https://www.ncbi.nlm.nih.gov/pubmed/29402886
http://dx.doi.org/10.1038/s41467-018-02885-x

Ejemplares similares